| This week's sponsor is Premier Research. | | | >From Lab to Bedside: The Latest Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
Top Stories Tuesday, February 7, 2017 FDA has lifted the partial clinical hold on Northwest Biotherapeutics’ phase 3 cancer vaccine trial. The action comes 18 months after FDA suspended the screening of new patients in the trial, and potentially just months before Northwest Bio hits the thresholds needed to wrap up the study. Tuesday, February 7, 2017 After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor. Tuesday, February 7, 2017 Prexton Therapeutics has raised €29 million ($31 million) to take its Parkinson’s disease candidate through two phase 2 trials. The Series B positions the Merck Serono spinout to build on last year’s phase 1 success by testing the mGluR4 positive allosteric modulator in larger efficacy studies. Tuesday, February 7, 2017 Gene therapy specialist Renova Therapeutics has strengthened its position in heart failure by licensing rights to an injectable peptide drug held by Janssen. Monday, February 6, 2017 Allurion Technologies raised $19 million of a $27 million offering. The Natick, Massachusetts-based company markets an ingestible weight-loss balloon in parts of Europe and the Middle East. Tuesday, February 7, 2017 Once again, we at FiercePharma and FierceBiotech are putting together a list of the year’s most influential people in biopharma. And we want your help. | | | The FDA will allow Cellectis to later this year start an early-stage test for its gene edited cell therapy in certain blood cancers. Reuters story Aurinia said it has given its founder Dr. Richard Glickman the CEO role at the biotech as Charles Rowland steps down. Release Vyome Biosciences has posted new data from its phase 1 test of VB-1953 in acne patients. Statement | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! BIO CEO & Investor Conference February 13 – 14, 2017 | The Waldorf Astoria, New York, NY Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA PEGS: The Essential Protein Engineering Summit May 1-5, 2017 | Boston, MA | 